Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care |
| Investment focus | Equity, World, Health Care, Social/Environmental |
| Fund size | GBP 8 m |
| Total expense ratio | 0.18% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Investment approach | Long-only |
| Sustainability | Yes |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in GBP) | 14.59% |
| Inception/ Listing Date | 12 April 2023 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | Invesco |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Investment Advisor | Invesco Capital Management LLC |
| Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
| Revision Company | PricewaterhouseCoopers |
| Fiscal Year End | 31 December |
| Swiss representative | BNP Paribas, Paris, succursale de Zurich |
| Swiss paying agent | BNP Paribas, Paris, succursale de Zurich |
| Germany | Unknown |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Italy | 26.0% |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | Yes |
| Securities lending counterparty |
| Eli Lilly & Co. | 12.60% |
| AbbVie, Inc. | 9.92% |
| AstraZeneca PLC | 5.69% |
| Merck & Co., Inc. | 5.66% |
| Roche Holding AG | 5.29% |
| Novartis AG | 4.62% |
| Abbott Laboratories | 4.20% |
| Gilead Sciences, Inc. | 3.94% |
| Amgen, Inc. | 3.38% |
| Thermo Fisher Scientific | 2.86% |
| United States | 66.22% |
| United Kingdom | 6.77% |
| Switzerland | 5.92% |
| Japan | 5.00% |
| Other | 16.09% |
| Health Care | 92.79% |
| Consumer Discretionary | 1.09% |
| Other | 6.12% |
| YTD | -4.92% |
| 1 month | +3.34% |
| 3 months | -7.01% |
| 6 months | -8.12% |
| 1 year | +14.00% |
| 3 years | +10.48% |
| 5 years | - |
| Since inception (MAX) | +6.67% |
| 2025 | +7.49% |
| 2024 | +3.18% |
| 2023 | - |
| 2022 | - |
| Volatility 1 year | 14.59% |
| Volatility 3 years | 13.85% |
| Volatility 5 years | - |
| Return per risk 1 year | 0.96 |
| Return per risk 3 years | 0.24 |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -13.39% |
| Maximum drawdown 3 years | -20.63% |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -20.63% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | WH2E | - - | - - | - |
| Borsa Italiana | EUR | WDHE | WDHE IM WHCEINE | WDHE.MI I2PZINAV.DE | Societe Generale |
| London Stock Exchange | GBX | WHCG | WHCG LN WHCEINS | WHCG.L I2P0INAV.DE | Societe Generale |
| London Stock Exchange | USD | WHCE | WHCE LN WHCEIN | WHCE.L I2P1INAV.DE | Societe Generale |
| SIX Swiss Exchange | USD | WHCE | WHCE SW WHCEIN | WHCE.S I2P1INAV.DE | Societe Generale |
| XETRA | EUR | WH2E | WH2E GY WHCEINE | WH2E.DE I2PZINAV.DE | Societe Generale |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 864 | 0.40% p.a. | Accumulating | Sampling |
| iShares Ageing Population UCITS ETF | 682 | 0.40% p.a. | Accumulating | Sampling |
| iShares MSCI World Health Care Sector Advanced UCITS ETF USD (Acc) | 265 | 0.18% p.a. | Accumulating | Full replication |
| Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 22 | 0.35% p.a. | Accumulating | Full replication |
| WisdomTree BioRevolution UCITS ETF USD Acc | 12 | 0.45% p.a. | Accumulating | Full replication |